Skip to main content

AZN · Astrazeneca PLC

Track AZN — free
$184.02 -0.43 (-0.23%) At close · Nov 16
Market Cap
$285.40B
Shares
1.55B
Volume · Nov 16 1.95M Avg daily vol (3M) 3.03M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$184.02 Open$186.91 Day$183.86–187.69 52W close$155.62–209.48 Avg vol 30d3.0M Short int3.0M · 0.2% of shares · 1.0d Short vol61% Last earningsOct 30, 2026 DataJan 2020–Nov 2026

Up next

Feb 9, 2027 Est · unconfirmed · in 12 wks
call held Apr 29, 2026

Latest documents

2026
Nov 16
Current report 6-K
Baxfendy recommended for EU hypertension approval

AstraZeneca said Baxfendy (baxdrostat) was recommended for EU approval for adults with uncontrolled hypertension. If approved, it would be the EU’s first and only aldosterone synthase inhibitor; two Phase III trials showed reductions of 15.7 mmHg and 16.6 mmHg in systolic blood pressure.

3 source passages
AstraZeneca's Baxfendy (baxdrostat) has been recommended for approval in the European Union (EU) for the treatment of adults with arterial hypertension insufficiently controlled with at least two antihypertensive medicinal products. If approved, Baxfendy will be the first and only aldosterone synthase inhibitor (ASI) in the EU, directly targeting aldosterone to address a key biological driver of elevated blood pressure. Baxfendy 2mg lowered office systolic blood pressure by 15.7 mmHg from baseline in BaxHTN trial and 24-hour ambulatory systolic blood pressure by 16.6 mmHg from baseline in Bax24 trial Open the document at this passage
Nov 16
Current report 6-K
Imfinzi plus EV approved in US for muscle-invasive bladder cancer

AstraZeneca’s Imfinzi plus EV (enfortumab vedotin) received US approval for perioperative treatment of adults with muscle-invasive bladder cancer ineligible for or refusing cisplatin-based chemotherapy. The VOLGA Phase III trial showed 49% lower recurrence risk and 42% lower death risk.

2 source passages
AstraZeneca’s Imfinzi (durvalumab) in combination with enfortumab vedotin (EV) as neoadjuvant treatment, followed by Imfinzi monotherapy as adjuvant treatment after radical cystectomy (surgery to remove the bladder), has been approved in the US for the treatment of adult patients with muscle-invasive bladder cancer (MIBC) who are ineligible for or have refused cisplatin-based chemotherapy. Based on VOLGA Phase III trial data which showed a 49% reduction in risk of recurrence and a 42% reduction in risk of death, with a manageable safety profile Open the document at this passage
Nov 16
Current report 6-K
Klygefa gains EU approval for generalised myasthenia gravis

AstraZeneca PLC reported that Klygefa (gefurulimab) received European Union (EU) approval as an add-on to standard therapy for adults with anti-acetylcholine receptor antibody-positive generalised myasthenia gravis, based on positive PREVAIL Phase III trial results.

4 source passages
AstraZeneca PLC Klygefa (gefurulimab) approved in the EU for the treatment of adults with generalised myasthenia gravis (gMG) Alexion, AstraZeneca Rare Disease’s Klygefa (gefurulimab) has been approved in the European Union (EU) as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody positive. Approval based on PREVAIL Phase III trial demonstrating statistically significant and clinically meaningful improvement in Myasthenia Gravis Activities of Daily Living score Open the document at this passage
Nov 2
Current report 6-K
11,948 Further Securities Admitted to London Stock Exchange

AstraZeneca PLC admitted 11,948 further securities to the London Stock Exchange - Main Market, bringing total securities in issue to 1,551,065,237; they were issued between 1 October 2026 to 31 October 2026 under employee share schemes.

6 source passages
AstraZeneca PLC 11,948 London Stock Exchange - Main Market 1,551,065,237 Issued between 1 October 2026 to 31 October 2026 Admission of shares under the Company’s employee share schemes Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$61.37B
Trailing 12 months
Net income (TTM)
$10.45B
Trailing 12 months
Revenue growth YoY
+6.4%
Year over year
Operating margin
22.8%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
3.7%
TTM · current market cap
Return on invested capital
16.4%
Trailing 12 months
Net cash
−$22.11B
Latest balance sheet
Dividend yield
1.2%
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
0.2%
Latest settlement · 1.0 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Strong Sentiment Neutral Fundamentals Limited Quant / Vol Moderate
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +2%
above
Price vs 50-day avg +9%
above
RSI (14) 61
neutral
MACD trend Negative
52-week position 53%
mid-range
Momentum
relative strength
Strong
1-month return +12%
trailing
6-month return −1%
trailing
YTD return 0%
this year
Relative strength +1%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $169 › 200d $180 — 200d above 50d
Institutional flow Distributing
-15% holders QoQ · +110 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.20% of shares out · ▼ -7.7% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
1,262 holders — mid 3-yr range
Squeeze score 45
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Moderate
Volatility 28%
annualized · 1-yr
Max drawdown −26%
past year
ATR 2.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Apr 29, 2026
Peak year sales · peak year at least $5B
Previous outlook earlier release · from the Earnings Call filed Feb 10, 2026

Still-open targets the latest release did not restate under the same label.

Success-based milestones and sales payments relating to past dea · In 2026 $2.5B
Annual declared dividend · In 2026 $3.30
Core tax rate · in 2026 18% – 22%
Peak-year sales for Ultomiris · peak-year sales at least $5B
The $80 billion ambition · by 2030 $80B

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+2% Bullish
Price vs 50-day avg
+9% Bullish
RSI (14)
61 Neutral
MACD trend
Negative Bearish
52-week position
53% Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $169 › 200d $180 — 200d above 50d
Institutional flow Distributing
-15% holders QoQ · +110 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.20% of shares out · ▼ -7.7% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
1,262 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $156 Now $184 · 53% Range high $209
vs 200-day avg +2% vs 50-day avg +9%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Drug Manufacturers - General — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
AZN
Astrazeneca PLC
this stock
$285.40B — — — 0.2%
LLY
ELI LILLY & Co
$1.35T +33.2% +44.7% 46.5 0.8%
JNJ
Johnson & Johnson
$680.19B +36.5% +6.0% 42.9 0.7%
ABBV
AbbVie Inc.
$520.65B +28.9% +8.6% 50.7 0.9%
MRK
Merck & Co., Inc.
$356.13B +37.2% +1.3% 148.9 1.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
1,262
% held
45.7%
Net QoQ
-98.4M sh
Top holder
VANGUARD CAPITAL MANAGEME…
Held Float
View
Held by Funds
Fund positions
150
View
Short & Settlement
Short Interest Falling
Shares short
3.0M
Days to cover
1.0d
Change
-251.3K sh
View
Short Volume
Short vol %
61%
As of
Nov 16, 2026
Short Total
View
Fails to Deliver
FTD shares
15.4K
Value
$2.6M
As of
Oct 29, 2026
View
Off-Exchange
Off-exchange %
47.1%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Buy
Member
Alan Armstrong
Amount
$1.0K–$15.0K
Traded
Mar 31, 2026
View
Filings
SEC Filings
Latest
6-K
Filed
Nov 16, 2026
This year
101

AstraZeneca’s Imfinzi plus EV (enfortumab vedotin) received US approval for perioperative treatment of adults with muscle-invasive bladder cancer ineligible for or refusing cisplatin-based chemotherapy. The VOLGA Phase III trial showed 49% lower recurrence risk and 42% lower death risk.

View
Proposed Sales
Value
$1.3M
Shares
15.0K
Filed
Nov 12, 2025
View
Earnings & Events
Webcasts
Last webcast
Oct 30, 2026
View

Performance

5D 20D 120D MTD YTD
AZN -2.8% +12.2% -0.9% -1.4% +0.1%
SPY -1.7% -3.5% -1.4% -2.1% +8.5%
vs SPY -1.2% +15.7% +0.5% +0.7% -8.4%

Capital returns

Latest dividend
$2.153 / share · ex Feb 19, 2026
Raised 109%
Paid (TTM)
$2.153 / share · 1 payout
Dividend yield (TTM, derived)
— · history filling in
Full dividend history

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 901832 CUSIP G0593M107 13F (30d) 1094 filings 1075 filers Visit website Investor relations